A team of investigators sought to determine the prevalence of definitive andindeterminate Pseudomonas aeruginosa pneumonia among patients with CAP.
Treatment with tocilizumab did not lead to improvement in clinical status and did not lower mortality at 28 days compared with placebo in hospitalized patients with severe pneumonia related to COVID-19.
Investigators assessed the cumulative incidence of acute cardiovascular complications during hospitalization for community-acquired pneumonia in internal medicine units.
Researchers studied macrolide resistance in patients with a positive S pneumoniae blood or respiratory culture.
The objective of this quasi-experimental observational study was to measure the effect of states’ hospital worker influenza vaccination laws on pneumonia and influenza mortality.
Findings from a retrospective chart review showed a need to carefully monitor inflammatory biomarkers and anticoagulant dosage in patients with severe COVID-19.
The REMDACTA study evaluated the efficacy and safety of tocilizumab plus remdesivir in hospitalized patients with severe COVID-19 pneumonia receiving standard of care.
For the treatment of community-acquired pneumonia, 5 days of antibiotic therapy is noninferior to standard of care.
The risk for stroke-associated pneumonia is reduced for those with psoriasis or other chronic inflammatory diseases.
Is testing for Legionella pneumophila appropriate and could it impact treatment?
Researchers assessed whether there was geographic variation in racial disparity in influenza and pneumonia.
There appears to be a low risk of invasive fungal secondary infection, especially aspergillosis, in patients with SARS-CoV-2-related pneumonia and no underlying immunosuppression.
Researchers assessed glucocorticoid maintenance dose and treatment duration on outcomes in patients with ANCA-associated vasculitis.
Investigators conducted the PlasmAr trial to evaluate the safety and efficacy of convalescent plasma in the treatment of SARS-CoV-2 pneumonia.
The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube.
Cadmium burden is associated with increased mortality from influenza or pneumonia in US adults.
Clinical status, mortality did not differ for convalescent plasma versus placebo in adults with severe COVID-19 pneumonia.
Researchers investigated the effects of ILI on pneumococcal carriage in community-dwelling older adults.
Study authors assessed the efficacy and safety of cefiderocol vs best available therapy in adults with serious carbapenem-resistant Gram-negative infections.
Researchers compared the efficacy and safety of cefiderocol vs high-dose, extended-infusion meropenem for adults with nosocomial pneumonia.